درباره این اپیزود
In Hims House episode 60, Sam Koppelman (co-founder of Hunterbrook Media) joins Jonathan Stern to break down the renewed Hims x Novo Nordisk partnership that sent Hims' stock soaring. Koppelman argues CEO Andrew Dudum "wiped the floor" with Novo, essentially conceding nothing beyond dropping compounded GLP-1 ads. They dig into why Novo folded, how FDA enforcement under Marty Makary has been softer than expected, and whether compounded GLP-1s will survive 2026. The conversation also turns to peptides as Hims' next major growth lever, powered by its own manufacturing facility and coming regulatory changes under RFK. Koppelman also discusses Hims vs Ro, and discloses that Hunterbrook Capital is currently long $HIMS.
00:00 - Sponsor: Mochi Health
02:39 - Hims x Novo are back!
07:40 - Why Dudum "wiped the floor" with Novo
11:38 - The semaglutide pill controversy
13:48 - Branded vs compounded GLP-1s
16:32 - Eli Lilly next?
17:36 - FDA enforcement since Makary
21:31 - Why peptides could be HUGE
30:57 - Hims subscriber growth and outlook
33:18 - Ro vs Hims
35:45 - Hunterbrook’s current Hims position 👀
Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.
